CUMYL-CBMINACA: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:CUMYL-CBMINACA}} | |||
== | == Overview == | ||
CUMYL-CBMINACA is a | [[File:CUMYL-CBMINACA_structure.png|thumb|right|Chemical structure of CUMYL-CBMINACA]] | ||
'''CUMYL-CBMINACA''' is a synthetic cannabinoid that acts as a potent agonist of the [[cannabinoid receptor]]s. It is part of a class of compounds that are often used in the manufacture of [[designer drugs]]. These substances are frequently found in products marketed as "[[spice (drug)|spice]]" or "synthetic marijuana". | |||
== | == Chemical Properties == | ||
CUMYL-CBMINACA | CUMYL-CBMINACA is chemically classified as an indazole-based synthetic cannabinoid. Its full chemical name is ''N''-[[(1-(cyclobutylmethyl)-1''H''-indazole-3-carbonyl)amino]]-3-methylbutanamide. The compound is known for its high affinity for the [[CB1 receptor|CB1]] and [[CB2 receptor|CB2]] receptors, which are part of the [[endocannabinoid system]]. | ||
== | == Pharmacology == | ||
CUMYL-CBMINACA | CUMYL-CBMINACA functions as a full agonist at the cannabinoid receptors, mimicking the effects of [[tetrahydrocannabinol]] (THC), the primary psychoactive component of [[cannabis]]. The activation of these receptors by CUMYL-CBMINACA can lead to a range of effects, including [[euphoria]], [[anxiety]], and [[hallucinations]]. | ||
== | == Legal Status == | ||
Due to its potential for abuse and lack of medical use, CUMYL-CBMINACA is classified as a controlled substance in many jurisdictions. It is often included in legislation targeting synthetic cannabinoids and other [[new psychoactive substances]] (NPS). | |||
== Health Effects == | |||
The use of CUMYL-CBMINACA has been associated with adverse health effects, including [[tachycardia]], [[hypertension]], [[nausea]], and [[vomiting]]. In severe cases, it can lead to [[seizures]], [[psychosis]], and even [[death]]. The variability in potency and the presence of unknown adulterants in products containing synthetic cannabinoids increase the risk of harmful effects. | |||
== Detection == | |||
CUMYL-CBMINACA can be detected in biological samples using advanced analytical techniques such as [[mass spectrometry]] and [[gas chromatography]]. These methods are essential for forensic investigations and for monitoring the presence of synthetic cannabinoids in the population. | |||
== Related Pages == | |||
* [[Synthetic cannabinoids]] | * [[Synthetic cannabinoids]] | ||
* [[ | * [[Cannabinoid receptor]] | ||
* [[Designer drugs]] | |||
* [[Spice (drug)]] | |||
[[Category:Synthetic cannabinoids]] | [[Category:Synthetic cannabinoids]] | ||
[[Category:Designer drugs]] | [[Category:Designer drugs]] | ||
Latest revision as of 05:30, 16 February 2025
Overview[edit]
CUMYL-CBMINACA is a synthetic cannabinoid that acts as a potent agonist of the cannabinoid receptors. It is part of a class of compounds that are often used in the manufacture of designer drugs. These substances are frequently found in products marketed as "spice" or "synthetic marijuana".
Chemical Properties[edit]
CUMYL-CBMINACA is chemically classified as an indazole-based synthetic cannabinoid. Its full chemical name is N-(1-(cyclobutylmethyl)-1''H''-indazole-3-carbonyl)amino-3-methylbutanamide. The compound is known for its high affinity for the CB1 and CB2 receptors, which are part of the endocannabinoid system.
Pharmacology[edit]
CUMYL-CBMINACA functions as a full agonist at the cannabinoid receptors, mimicking the effects of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. The activation of these receptors by CUMYL-CBMINACA can lead to a range of effects, including euphoria, anxiety, and hallucinations.
Legal Status[edit]
Due to its potential for abuse and lack of medical use, CUMYL-CBMINACA is classified as a controlled substance in many jurisdictions. It is often included in legislation targeting synthetic cannabinoids and other new psychoactive substances (NPS).
Health Effects[edit]
The use of CUMYL-CBMINACA has been associated with adverse health effects, including tachycardia, hypertension, nausea, and vomiting. In severe cases, it can lead to seizures, psychosis, and even death. The variability in potency and the presence of unknown adulterants in products containing synthetic cannabinoids increase the risk of harmful effects.
Detection[edit]
CUMYL-CBMINACA can be detected in biological samples using advanced analytical techniques such as mass spectrometry and gas chromatography. These methods are essential for forensic investigations and for monitoring the presence of synthetic cannabinoids in the population.
